Leqembi Iqlik
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection. In clinical trials, it demonstrated small or no clinically significant efficacy in Alzheimer's disease. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid. Lecanemab was jointly developed by Eisai, Biogen, and Bioarctic.
Beyond's analysis on Leqembi Iqlik
- — FDA approves subcutaneous Leqembi for early Alzheimer’s, enabling once‑weekly dosing
- — FDA’s approval of a subcutaneous starting dose for Leqembi Iqlik opens a new at‑home dosing option for early Alzheimer’s, potentially expanding patient access and driving uptake of Eisai‑BioArctic’s anti‑amyloid therapy
Recent news mentioning Leqembi Iqlik
- — Leqembi Iqlik® for initiation treatment launched in the US
- — Leqembi Iqlik® for initiation treatment launched in the US
- — LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- — FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- — FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- — FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- — FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease